[Effectiveness and tolerance of combined verapamil retard and hydrochlorothiazide. Results of a double-blind, randomized study].
OBJECTIVE
To determine, in a multicenter study, whether the fixed combination of verapamil retard (240 mg) and hydrochlorothiazide (12.5 mg) is capable of lowering blood pressure more effectively than either of the substances alone or placebo, while retaining good tolerability.


METHODS
A total of 173 patients who, after a four-week run-in period had a diastolic blood pressure of at least 100 and not more than 115 mm Hg, were randomized to six weeks of monotherapy with one of the two substances, placebo or the fixed combination.


RESULTS
Combination treatment proved superior to monotherapy with either substance in lowering the diastolic blood pressure (p < 0.05). Also in terms of normalization (diastolic pressure < 90 mm Hg) the combination was clearly superior (p < 0.05). During the study no side effects beyond those associated with the single substances, occurred.
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001317:Austria; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D005858:Germany; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage* / Q000009:adverse effects; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014700:Verapamil / Q000008:administration & dosage* / Q000009:adverse effects
D000959:Antihypertensive Agents; D003692:Delayed-Action Preparations; D006852:Hydrochlorothiazide; D014700:Verapamil
Wirksamkeit und Verträglichkeit der Kombination Verapamil retard und Hydrochlorothiazid. Ergebnisse einer doppelblinden, randomisierten Studie.